UPDATE: Alexion Pharma (ALXN) Reports Q2 Revenue of $753M; Trims FY16 Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- Tech stocks power S&P 500 to record high as oil prices, producer inflation ease
- Oil pares losses after reports Houthis attacked Saudi Aramco refinery
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Alexion Reports Second Quarter 2016 Results
July 28, 2016 6:30 AM EDT- Total Revenues of $753 Million; Increased 18 Percent Year-on-Year; 23 Percent Volume Increase Year-on-Year-
- Soliris® (eculizumab) Revenue Growth Driven by Steady Number of New Patients with PNH and aHUS Treated Globally -
- Strong Strensiq® (asfotase alfa) Launch Continues in Initial Countries -
- Kanuma® (sebelipase alfa) Launch Progresses with Newly Identified Patients Starting on Treatment -
- Eculizumab Phase 3 REGAIN Data in Refractory gMG Presented at the ICNMD Congress -
- ALXN1210 Phase 1/2 Data Showed Rapid and Sustained Reductions in LDH in All... More
